G1 Therapeutics jumps 16.9% as trilaciclib wins FDA approval Looking for Alpha
FDA approves G1 Therapeutics’ COSELA tr (trilaciclib): the first and only myelosuppression treatment to reduce the incidence of chemotherapy-induced myelosuppression Yahoo Finance
FDA approves Trilaciclib for chemo-treated patients with SCLC Cancer Network
FDA approves Trilaciclib to reduce chemo-induced bone marrow suppression in ES-SCLC OncLive
FDA approves G1 Therapeutics’ COSELA tr (trilaciclib): the first and only myelosuppression treatment to reduce the incidence of myelosuppression caused by chemotherapy GlobeNewswire